2015

1. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

   Circulation, Vol. 132, Núm. 1, pp. 27-39

2. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial

   Clinical Journal of the American Society of Nephrology, Vol. 10, Núm. 5, pp. 791-799